Department of Medicine Archives
Jan. 10, 2019—A large-scale study conducted among East Asians and led by Vanderbilt researchers has identified multiple, previously unknown genetic risk factors for colorectal cancer.
Jan. 10, 2019—Craig Lindsley, PhD, a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is being honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) for his transformative approaches to identifying potential new drugs.
Jan. 10, 2019—A team of Vanderbilt investigators has pinpointed the role of bile acids and a specific signaling pathway in the positive metabolic effects of weight-loss surgery.
Dec. 31, 2018— by Bill Snyder In one of the largest studies of its kind, an international research team led by 20 Vanderbilt University scientists has discovered more than 200 new genetic variations associated with high blood pressure. The study, published December 21 by the journal Nature Genetics, also identified specific tissues where blood pressure genes exert...
Dec. 13, 2018—Mary Philip, MD, PhD, has been named a 2019 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.
Dec. 6, 2018—William Schaffner, MD, professor of Preventive Medicine in the Department of Health Policy and professor of Medicine in the Division of Infectious Diseases, is the recipient of the 2018 D.A. Henderson Award for Outstanding Contributions to Public Health.
Nov. 29, 2018—Former sports journalist Joe Lofaro has little memory of Oct. 23, 2015, when his son Daniel loaded him into a car at his Martin, Tennessee, home and said, ‘Come on, Dad, we’re going for a ride.”
Nov. 15, 2018—David G. Harrison, MD, the Betty and Jack Bailey Professor of Cardiology and director of the Division of Clinical Pharmacology at Vanderbilt University School of Medicine, has been awarded the American Heart Association’s Basic Research Prize for 2018.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.